Panag Pharma announces Health Canada approval for a topical Cold-Sore Formulation, a new generation topical formulation with a dual mechanism of action that improves healing rates and reduces symptoms.
Panag Pharma, Inc. launched a clinical trial evaluating the use of the newly NHP registered product Topical AOTC, a new generation topical for pain and pain associated with inflammation.
Halifax, Nova Scotia. Panag Pharma announces Health Canada approval for Topical AOTC, a new generation topical formulation with a dual mechanism of action against pain. Topical AOTC is a natural health product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and sprains and arthritis.
Topical AOTC uses a novel technology targeting the endocannabinoid system and TRPV1 receptors, both known to play a key role in modulation of pain. There is no other similar product on the market. Panag Pharma will move forward with a regional launch of Topical AOTC to selected clinics in early 2017. Learn more about Topical AOTC
About Panag Pharma Inc.
Panag Pharma is a Halifax, Nova Scotia based Life Sciences company developing a range of products which provide relief from chronic pain and inflammation, especially in sensitive sites, using proprietary plant-derived compounds. Learn more…
Latest Panag Pharma News
Panag Pharma Inc.